Lawmakers urge FDA to enact new China policies after 3 gene therapy deaths

Following three patient deaths in gene therapy clinical trials in China, U.S. lawmakers urged the FDA to tighten policies on accepting Chinese clinical data, including requiring recent FDA audits of trial sites and reviewing products approved based on such data.

This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 21 Aug 2026 and 3 Sep 2026.